Department of Medicinal Chemistry, New Drug Discovery Research, Ranbaxy Research Laboratories, Plot-20, Sector-18, Udyog Vihar, Gurgaon 122001, India.
Bioorg Med Chem Lett. 2012 Jan 1;22(1):476-81. doi: 10.1016/j.bmcl.2011.10.101. Epub 2011 Nov 9.
A novel series of acylides 4 were designed to overcome antibacterial resistance and evaluated for in vitro and in vivo activity. This series of acylides was designed from clarithromycin by changing the substitution on the desosamine nitrogen, followed by conversion to 3-O-acyl and 11,12-carbamate. These compounds showed significantly potent antibacterial activity against not only Gram-positive pathogens, including macrolide-lincosamide-streptogramin B (MLS(B))-resistant and efflux-resistant strains, but also Gram-negative pathogens such as Haemophilus influenzae. These acylides also showed better activity against telithromycin resistant Streptococcus pneumoniae strains.
设计了一系列新型酰基化物 4 以克服抗菌耐药性,并评估了其体外和体内活性。该系列酰基化物是通过改变克拉霉素中去氧氨基上的取代基设计而来,然后转化为 3-O-酰基和 11,12-氨基甲酸酯。这些化合物不仅对革兰氏阳性病原体(包括大环内酯-林可酰胺-链阳性菌素 B(MLS(B))耐药和外排耐药株)具有显著的强大抗菌活性,而且对流感嗜血杆菌等革兰氏阴性病原体也具有活性。这些酰基化物对耐克拉霉素的肺炎链球菌株也显示出更好的活性。